CD33 and cancer: In addition, mass spectrometry (MS)-based analysis of released N-glycans from cancer patient-derived CD33+ cells revealed a clear increase in the abundance of terminally sialylated N-glycans containing multiple sialic acids compared to that in myeloid cells from healthy donors (Fig. 2C, D).